Approximately 20% of adults experience a mental health issue in any given year worldwide.

Public Health, Prevention & Behaviour Change

Current research into psychedelics as a means of public health intervention highlights their potential in addressing various behavioural health conditions. As clinical trials expand, the implications for prevention and behaviour change are becoming increasingly apparent.

What is Public Health, Prevention & Behaviour Change?

Public health encompasses the study of health promotion, disease prevention, and behaviour change at a population level, focusing on improving health outcomes.

Behavioural health conditions, including substance use disorders and mental health issues, can be influenced significantly by social and environmental factors that require community-level interventions.

Emerging evidence suggests that psychedelics, including compounds such as psilocybin and MDMA, may play a role in enhancing therapeutic approaches to address these conditions through their effects on emotional and cognitive processes.

Current Treatments

Standard-of-care treatments for behavioural health conditions typically include psychotherapy, cognitive-behavioural therapies, and pharmacological interventions such as antidepressants and anti-anxiety medications.

Psychedelic Effect Matrix

Systematic comparison of compound efficacy and evidence levels for Public Health, Prevention & Behaviour Change.

Compound	Magnitude	Evidence	Consistency
Psilocybin Numerous clinical trials demonstrate psilocybin's efficacy in treating major depression and anxiety associated with terminal illness.	Large	High	Consistent
MDMA Multiple phase 3 trials support MDMA-assisted therapy for PTSD, showing marked improvement in clinical outcomes.	Large	High	Highly Consistent
LSD Some studies suggest LSD can enhance creative problem-solving and emotional processing, though robust evidence is still pending.	Medium	Moderate	Inconsistent
Ayahuasca There are promising results regarding Ayahuasca's potential to facilitate psychological insights and behavioural change, but evidence remains early-stage.	Medium	Moderate	Inconsistent
Ketamine Ketamine has shown rapid antidepressant effects in treatment-resistant depression, supporting its therapeutic potential.	Large	High	Consistent

Psilocybin and Public Health, Prevention & Behaviour Change

Psilocybin, the active compound in magic mushrooms, has been shown to produce profound changes in perception, mood, and cognition. Research indicates that it can facilitate therapeutic breakthroughs in behavioural health by enabling patients to re-examine their life perspectives, thereby aiding in the treatment of anxiety, depression, and addiction.

View full Psilocybin profile →

MDMA and Public Health, Prevention & Behaviour Change

MDMA, commonly known as ecstasy, has therapeutic applications in PTSD treatment. It enhances emotional engagement and decreases fear response, allowing patients to revisit trauma in a safe, guided therapeutic setting. This compound has undergone extensive study, resulting in consistent improvements in clinical outcomes for individuals suffering from trauma-related conditions.

View full MDMA profile →

Ketamine and Public Health, Prevention & Behaviour Change

Ketamine, traditionally an anaesthetic, has emerged as a fast-acting antidepressant for individuals with severe depression. Its mechanism of action appears to involve the modulation of glutamate, leading to synaptic plasticity and rejuvenation of neural connections, contributing to lasting behavioural change.

View full Ketamine profile →

Key Insights

1
Psychedelics have been observed to create lasting changes in behaviour and emotional regulation, which are promising for therapeutic interventions.
2
Current psychedelic research largely involves observational and retrospective studies, necessitating more robust randomised clinical trials.
3
Public health approaches incorporating psychedelics are rapidly evolving, with potential to address equity in mental health treatment access.

Industrial Landscape

Key players in the research and implementation of psychedelics include academic institutions, non-profit organisations focused on mental health, and pharmaceutical companies exploring the therapeutic potentials of psychedelic compounds.

Quick Indicators

PrevalenceApproximately 20% of adults experience a mental health issue in any given year worldwide.

Research Footprint

0Trials

0Papers

\"Ongoing clinical evaluations are investigating Public Health, Prevention & Behaviour Change as a primary indication for various psychedelic compounds.\"

Key Organizations

4 Connected

Delix Therapeutics

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

MAPS

The description of the stakeholder

Lykos Therapeutics

Longer description of Lykos .. lorem ipsum ..

Leiden University

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.